Clinical Trials Logo

Clinical Trial Summary

Despite the progression in assisted reproductive technology (ART), the preferred protocol for poor responders is still controversial. The management of poor responders consists of 10% of ART cycles .

The response to controlled ovarian hyperstimulation (COH) is lower regarding estradiol level , number of obtained oocytes , and fertilization , implantation and pregnancy rates in patients with low ovarian reserve . Furthermore , bad quality embryos are observed in these women more than normoresponders and the increase of cancellation rate and doses of gonadotropin administration are remarkable results in poor responders . Several criteria have introduced for poor responders , the main defect in the management of them is lack of specific definition .Several strategies are available to improve ART cycles outcome in poor responders. These modalities include using : high FSH dose , stop GnRH-agonist protocol , addition of growth hormone , transdermal testosterone , aromatase inhibitor , GnRH-antagonist and recombinant FSH ( r-FSH) ; while the improvement of pregnancy rate has been quite low.

The most common used protocol for ovarian stimulation is microdose GnRH-agonist flare in poor responders .Some investigators concluded that the use of GnRH-agonist " even in lower doses , led to prolonged stimulation and increased the cost without improving IVF outcome. Furthermore this method increased LH , progesterone and androgen of serum in follicular phase , which caused deleterious effect on follicular growth and oocyte quality .

Clomiphene citrate co-treatment with gonadotropin and antagonist are one of the recommended protocol in poor responders . Clomiphene citrate increases endogenous FSH versus agonist in microdose protocol. Decreasing the doses of used gonadotropin and duration of stimulation are its beneficial effects in COH cycle .

The aim of this study was comparing CC/gonadotropin/antagonist and GnRH agonist flare protocols on IVF outcome in poor responders .


Clinical Trial Description

Despite the progression in assisted reproductive technology (ART) , the preferred protocol for poor responders is still controversial. The management of poor responders consists of 10% of ART cycles .

The response to controlled ovarian hyperstimulation (COH) is lower regarding estradiol (E₂) level , number of obtained oocytes , and fertilization , implantation and pregnancy rates in patients with low ovarian reserve . Furthermore , bad quality embryos are observed in these women more than normoresponders and the increase of cancellation rate and doses of gonadotropin administration are remarkable results in poor responders Several criteria have introduced for poor responders , the main defect in the management of them is lack of specific definition .Several strategies are available to improve ART cycles outcome in poor responders. These modalities include using : high FSH dose , stop GnRH-agonist protocol , addition of growth hormone , transdermal testosterone , aromatase inhibitor , GnRH-antagonist and recombinant FSH ( r-FSH) ; while the improvement of pregnancy rate has been quite low.

The most common used protocol for ovarian stimulation is microdose GnRH-agonist flare in poor responders .Some investigators concluded that the use of GnRH-agonist " even in lower doses " led to prolonged stimulation and increased the cost without improving IVF outcome. Furthermore this method increased LH , progesterone and androgen of serum in follicular phase , which caused deleterious effect on follicular growth and oocyte quality .

Clomiphene citrate co-treatment with gonadotropin and antagonist are one of the recommended protocol in poor responders . Clomiphene citrate increases endogenous FSH versus agonist in microdose protocol. Decreasing the doses of used gonadotropin and duration of stimulation are its beneficial effects in COH cycle .

The aim of this study was comparing CC/gonadotropin/antagonist and GnRH agonist flare protocols on IVF outcome in poor responders .

Materials and Methods Study design This study was a prospective randomized controlled trial including 159 poor responder patients who were candidate for IVF . Women with ≥38 years old who had one or more previous failed IVF cycles in which three or fewer oocyte were been retrieved and/or serum E2 level on the day of hCG administration was ≤500 pg/ml were enrolled in this study . Patients with BMI > 30 , endocrine or metabolic disorders , history of ovarian surgery , sever endometriosis and sever male factor ( azospermia ) were excluded from the study . Patients were divided into two groups , 79 women in group I received CC/gonadotropin/antagonist (mild protocol) and 80 women in group II received microdose GnRH-agonist flare (microdose protocol) . A method of computer-generated randomization was used .

Treatment Protocols All women received oral contraceptive for 21 days which started on the first day of previous cycle . In group I , stimulation were performed by administration of clomiphene citrate (Iran hormone, Tehran, Iran) 100 mg from day 3 of withdrawal bleeding until day 7 of cycle and gonadotropin stimulation with 225-300 IU daily , recombinant FSH (r-FSH) SC or hMG IM , were started from day 5 of cycle . In group II ovarian stimulation was initiated with GnRH-agonist , buserelin (Suprefact, Aventis Pharma, Frankfurt, Germany) 50 µg SC twice a day from cycle day 2 of withdrawal bleeding . After two days , 225-300 IU/day recombinant FSH (r-FSH) SC or hMG IM were administered.

Ovarian response was monitored by serial ultrasound examinations and evaluation of serum E₂ levels , then doses of gonadotropin were adjusted as required in both groups.

In group I , when at least one follicle ≥ 14 mm in mean diameter was observed , 0.25 mg GnRH antagonist (ganirelix , Organon, netherlands) SC daily was started and continued until hCG injection . Urinary Human chorionic gonadotropin 10000 IU was administered intramuscular when at least two follicles reached a mean diameter of 18 mm in both groups . Also , endometrial thickness and serum E₂ level were measured on the day of hCG injection .Oocyte retrieval was performed 34-36 hours after hCG injection and conventional IVF or intracytoplasmic sperm injection (ICSI) was done as appropriately . All embryos were scored by the number , size , shape , symmetry and cytoplasmic appearance of blastomers , and the presence of anucleate cytoplasmic fragmentation .

Based on the number and quality of available embryos and patient's age , one to five embryos were transferred on the day 2 or 3 after oocyte retrieval under ultrasound guidance with a CCD embryo transfer catheter (Laboratory C.C.D., Paris, France). Luteal support with progesterone 100 mg daily IM was started on the day of oocyte retrieval and was continued until the documentation of fetal heart activity on ultrasound.

Cycle cancellation was defined as three groups : [1] poor ovarian response : fewer than two growing follicles on transvaginal ultrasound, and an E₂ level < 200 pg/ml on the day 7 of stimulation ; [2] failed oocyte retrieval : no obtained oocyte on the day of ovarian puncture ; [3] failed fertilization : no fertilized oocyte after IVF/ICSI. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01213147
Study type Interventional
Source Yazd Medical University
Contact
Status Completed
Phase Phase 4
Start date April 2009
Completion date May 2010

See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Completed NCT02523755 - Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia Phase 4